Impact of spiritual healing on moderate depression in adults: a study protocol of a pilot randomised controlled trial (RCT)

Trine Stub,1 Audun Campell Irgens,2 Anne Helen Hansen,3,4 Olav Knudsen-Baas,2 Cornelia Gåskjenn,5 Agnete E Kristoffersen

ABSTRACT

Introduction Depression is a common mental disorder and the (global) leading cause of all non-fatal burden of disease worldwide. Currently, supported treatment for depression is antidepressant medication and different psychotherapeutic interventions. Many patients experience, however, adverse effects of antidepressant medication, while at the same time the access to psychotherapeutic interventions are limited. Many patients who suffer from depression turn to complementary medicine and among those modalities often spiritual healing. There is some evidence that consulting a spiritual healer can be beneficial for patients who suffer from depression, and that spiritual healing is associated with low risk. The aim of this protocol is to conduct a pilot randomised controlled trial (RCT) (spiritual healing as addition to usual care vs usual care alone) in preparation of a larger trial in adults with moderate depression, to examine feasibility and individuals’ experience of spiritual healing.

Methods and analysis This study is a pilot RCT with two parallel groups. A total of 28 adult patients with moderate depression, diagnosed by the physician and according to the Montgomery and Åsberg Depression Rating Scale criteria will be randomised to spiritual healing in addition to usual care (n=14) or usual care alone (n=14). To determine if there is a statistical indication of an effect of healing warranting a full-scale study; the separation test will be used. To investigate participants’ experience with spiritual healing, a qualitative study will be included using semistructured interviews. The data will be analysed based on a direct content analysis.

Ethics and dissemination This protocol was approved by regional committees for medical and health research ethics by the identifier (63692). The results will be disseminated through open-access, peer-reviewed publications, in addition to stakeholders’ reporting and presenting at conferences.

Trial registration Norwegian Centre for Research Data (845302) and clinicaltrials.gov (ID: NCT04766242)

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Several physicians will recruit patients to the trial providing insight into different methods of usual care.
⇒ Because of the COVID-19 lockdown, only one healer will be implementing the healing sessions as opposed to the two originally planned.
⇒ A multidisciplinary research team consisting of complementary medicine providers, physicians, psychiatrists and researchers safeguard a whole system research approach.
⇒ To enhance patient safety, the research team will record adverse effects of both healing and usual care.
⇒ Due to the overload of patients and COVID-19 protocols, the implementation of the trial has been negatively affected.

INTRODUCTION

Depression is a common mental disorder and is together with anxiety the (global) leading cause of all non-fatal burden of disease worldwide.1 The core symptoms of depression are lowered mood, discouragement, loss of sense and meaning in life, lack of interest in other people and ordinary duties, and lack of energy and appetite. In addition, the patients often experience diminished self-esteem, self-reproach and a feeling of guilt. These symptoms may vary in intensity and duration.2 3 Nevertheless, around half of all people with depression worldwide do not receive appropriate treatment.4 Most mental disorders emerge before the age of 30,5 6 and lack of treatment might contribute to disability for many crucial years of an individual’s life. In Norway, the 12-month prevalence and lifetime prevalence of depression is 10% and 20%, respectively, higher in women than in men.2 Depression has been identified as a strong predictor for use of complementary medicine (CM).5 6 A recent Norwegian study demonstrates that only 10.9% of those with moderate depression and/or anxiety visited psychiatric outpatient services while 17.6% visited a CM provider.10 These facts
demonstrate that people with depression might be willing to seek help also from less established services, such as CM providers. Thus, it is possible that different CM modalities may serve as a substitute or an alternative when access to psychologist/psychiatric services is limited.16 12

Conventional medicine classifies depression as a mood disorder that manifests itself across a wide range of disease/symptom severity. Depression can be classified as mild, moderate or severe.15 Symptoms must have been persistent for at least 2 weeks and not be related to other medical or psychiatric diagnoses, or be due to substances.14 The World Health Organization (WHO) ranks the social costs of depression as the fourth highest of all diseases.15 Furthermore, by 2020 current trends indicate that depression will represent the highest cost for society of any disease.15 Clearly, prevention, early diagnosis and intervention of depression have huge significance.

The most commonly prescribed antidepressant drug, selective serotonin reuptake inhibitors (SSRIs), has recently been shown to have the best effect on severe depression, and no effect beyond placebo for mild and moderate depression.16 17 At the same time, SSRIs can be associated with serious adverse effects,18 and are associated with increased vulnerability to develop a depressive episode later in life.16 Thus, one of the most common treatment options for depression has been documented to be of little or no help beyond placebo for moderate depression while at the same time possibly inducing serious adverse effects.

The Competence Center for Lived Experience and Service Development, investigates the needs for individuals with mental health problems. According to the centre, many patients in psychological healthcare do not want to be treated with medication. These patients must be heard and taken seriously. We cannot force anyone to take medication as long as necessary care and treatment can be provided otherwise.19

Cognitive behavioural therapy (CBT) or structured psychological therapy20 is a treatment option for patients who do not want pharmaceutical antidepressant treatment. However, waiting lists for such treatment are often long due to the lack of competent professionals (psychologists and psychiatrists), especially in rural communities, and at the district psychiatric centres.21 These centres have to prioritise patients with major depression, meaning that patients with moderate depression have less access to CBT.

**Spiritual healing for depression**

Spiritual healing is one of the most frequently used CM modalities in Norway.22 It is understood as an energy-based therapeutic approach to healing. A spiritual healer uses the hands to balance and harmonise the body and thereby place the client in a position of self-healing.23 The healing treatment focuses on the whole person (physically, psychologically and emotionally) as well as the environmental factors (support from family, friends, community). Scientific evidence indicates that users typically praise CM modalities for offering symptoms relief, reducing adverse effects of conventional treatment, enhancing their ability to cope physiologically and emotionally, providing an alternative to pharmaceuticals, and offering a close patient-practitioner relationship during treatment.24

There is some evidence that spiritual healing can be beneficial for patients who suffer from depression,25 26 and spiritual healing is associated with low risk.27 In a preliminary study conducted by the current research group, a mean decrease in depression score of 3.1 points (range 0–4) on a 7-point scale was found (n=9).28 The symptom was rated on a scale from 0 to 6 where 0 was ‘as good as it could be’ and 6 was ‘as bad as it could be’ (Measure Yourself Medical Outcome Profile (MYMOP) Scale29). Only one patient reported no change in depression symptoms after healing treatment. None of the patients experienced worsening of depression symptoms during the healing treatment, while the majority (n=5) had a reduction of 4 points.28 More research is needed to confirm these findings and to identify modifications needed in the design of a larger randomised controlled trial (RCT).

**Objectives**

The objectives of this study are to conduct a pilot RCT (spiritual healing as addition to usual care vs usual care alone) in preparation of a larger trial in adults with moderate depression, and further to examine the feasibility of the study design and the participants’ experience of spiritual healing.

**METHODS AND ANALYSIS**

This is a multicentre pilot RCT with two parallel arms. Nested within the trial is a qualitative arm.

**Design**

A total of 28 individuals with moderate depression will be randomised to a spiritual healing intervention as an adjunct to usual care (n=14) or to usual care alone (control) (n=14). We will study the entire spiritual healing package understood as everything a healer does in a consultation (visiting a healer), including the use of hands to balance and harmonise the body and sometimes offering lifestyle advice. Included in the treatment is the interaction between the patient and the therapist. A positive interaction between the patient and the therapist (alliance) is necessary for the patient to feel free to verbally express painful present and past experiences that may be related to the patient’s psychological complaints30 31 (eg, pragmatic research approach).

**Setting**

In Norway, inhabitants receive treatment within the public healthcare system, while CM providers, including healers, operate outside this system. Patients generally cover the cost of these visits themselves. Since CM
practices are unregulated, anyone is allowed to use the
term healer and treat patients. However, many healers
are members of the Norwegian Healing Association that
require a professional standard regarding healing skills.
To ensure patient safety in cases of interventions related
to health issues, members are required to obtain a profes-
sional insurance for injury to their patients caused by the
treatment.

Study participants
Inclusion criteria
All patients must be 18 years or above. They have to suffer
from depressive difficulties of moderate intensity and
fulfil the criteria for depression diagnosed by the physi-
cians included in the study, and score within the range of
20–29 on the Montgomery and Åsberg Depression Rating
Scale (MADRS) Depression Rating Scale.32 33 Symptoms
must have persisted for 2 weeks or more. In addition to
a MADRS Score of 20–29, the physicians who include
patients will decide whether the patient is suited for inclu-
sion based on the following observations: (1) The patient
is too healthy to be referred to a district psychiatric centre
and (2) The patient is too ill to remain untreated.

Exclusion criteria
Patients are excluded for the following reasons: Chronic
major or bipolar depression or any personality disorder
(axis II); endocrine abnormality; suicidal potential;
dementia; depression as direct physiological effects of a
substance or a medical condition (such as Parkinson’s
disease, epilepsy and multiple sclerosis); substance abuse;
history of psychosis or mania; heart valve disease; poorly
controlled hypertension and diabetes mellitus; preg-
nancy,34 or inability to complete study forms.

Recruitment
Patients who visit their physician for mood-related symp-
toms and fulfil the inclusion and do not fulfil any of the
exclusion criteria will be asked by the physician if they
want information about the study. If the patients agree,
they will receive an information folder and informed
consent. After that, the physician will send an Short
Message Service (SMS) with contact information to the
researchers at The National Center for Complementa-
ry Medicine (NAFKAM). Subsequently, NAFKAM will
contact the patients, inform further about the study and
include those who agree to participate. Before rando-
misation, participants must read and sign the informed
consent. To collect baseline data, a link to the electronic
Beck Depression Inventory (BDI) form will be forwarded
to the participants.

Randomisation
We will use a randomisation system with block sizes,
that vary from two to six, to eliminate confounders of a
personnel or structural nature, thus balancing group allo-
cation throughout the study period. Within each block,
an equal number of patients will be randomly allocated
to either an intervention group with spiritual healing and
usual care, or a control group with usual care alone.

Blinding
Patients will not be blinded regarding treatment alloca-
tion, in accordance with a pragmatic research approach.
Neither the study physicians nor the study therapist will be
blinded. The researchers will be blinded when analysing
unidentified patient-reported data.

INTERVENTION
Primary outcome measures
The study outcome will be recruitment speed, willingness
to be randomised, study adherence and implementa-
tion of healing compared with usual care for moderate
depression.

Secondary outcome measures
Secondary outcomes will be change in severity of depres-
sion measured by BDI.35 This questionnaire will be
completed by the study patients at baseline, after 8 weeks
and 16 weeks, and 6 months and 12 months after inclu-
sion to the study. The separation test36 will be used to
investigate an indication of an effect of healing in a full-
scale study.

An adverse effect form will be completed after 8 weeks
and 16 weeks. The RELIS (a national network of four
regional medicines information and pharmacovigilance
centres in Norway) Adverse Effect Scale37 will be used to
measure adverse effects and the questions about adverse
effects will be included at the end of the BDI form.

Measurements
The Beck Depression Inventory for Primary Care (BDI-
PC)35 is a screening instrument for depression that mini-
mises the possibility of yielding spuriously high estimates
depression for patients with medical problems by
focusing on symptoms of sadness, pessimism, past failure,
loss of pleasure (anhedonia), self-dislike, self-criticalness, and
suicidal thoughts or wishes. Each item is rated on a 4-point
scale ranging from 0 to 3. The highest rating for each of
the seven items constitute the total BDI-PC score.

To address the minimum Diagnostic and Statistical
Manual of Mental Disorders IV requirement for the dura-
tion of moderate depression symptoms, respondents
are asked to describe themselves for the ‘past 2 weeks,
including today’. We will also collect demographic data
such as age, gender, education, household income and
work, in addition to use of drugs and diary supplements/
herbs for depression (questionnaire baseline). In inter-
vention weeks 10 and 16, and 6 months and 12 months,
adverse effects and change in use of drugs and diary
supplements/herbs will be registered.

Qualitative study
In a qualitative study, nested within the trial, the investiga-
tors will investigate participants’ experiences of spiritual
**Figure 1** Flow chart of the schedule of enrolment, intervention and assessment. BDI, Beck Depression Inventory; MADRS, Montgomery and Åsberg Depression Rating Scale.
healing and usual care. The aim of the study is to collect information about the participants’ lived experience of participating in the trial receiving healing and usual care interventions. The study is based on phenomenology as this study design explores what people experienced and focuses on their experience of a phenomenon and will provide the investigators with more nuanced and in-depth data than data obtained only from the questionnaires.

The study will draw on data obtained through semistructured interviews conducted with 16 participants (n=16), eight (n=8) in the intervention group and eight (n=8) in the control group on completion of the intervention period (week 16).

Based on an interview guide, the participants will be asked about their illness (severity, duration, previous treatment), how they experienced the treatment (advantages and disadvantages) provided during the study, if their expectations were met and their willingness to be randomised. Furthermore, we will ask about adverse effects from the treatment, and the patient-provider relationship. The control group will be interviewed and asked about their experiences with usual care. Moreover, we will observe and register recruitment speed, study adherence and implementation of healing compared with usual care.

Treatment plan
The study is planned to start in March 2022 and the end of the study (data collection) is in March 2023.

Intervention
Spiritual healing will be based on an assessment of the total health situation of the individual patient. Spiritual healing will mainly consist of a treatment where the healers hold their hands for some time at different parts of the patient’s body, known as ‘power points’, outside the patient’s clothing. The consultation might also include lifestyle advice. This can necessarily lead to slightly different treatment given to each patient. Each treatment will, however, last for 45–60 min.

The healer who will perform the healing is a trained member of the Norwegian Healer Association (Norges Healerforbund). She has been working full time as a spiritual healer for more than 20 years. As a member of the Norwegian Healer Association, she has liability insurance in cases of harmful effects of the treatment.

Usual care
All participants will be advised to follow the treatment plan given by the physician at five different clinics in a town south in Norway. Usual care may include regular consultations with physicians (every 14th day, duration 30–60 min) including counselling about sleep, activity, lifestyle, antidepressive medication and sick leave. The participants in the control group will be offered three healing sessions after the 10-week intervention period.

Implementation
The study nurse at NAFKAM will send the link to the questionnaire to the participants at baseline, weeks 8 and 16, and after 6 months and 12 months, asking them to complete the questionnaire.

Follow-up
1. The study nurse will ask the participants to complete the electronic BDI Questionnaire in weeks 8 and 16. In addition, they will be asked to register information about adverse effects as part of the form.
2. The study nurse will contact the participants after 6 months and 12 months and remind them to complete the electronic BDI Questionnaire (follow-up data).
3. Interviews will be conducted with participants in both groups at the end of the intervention period (week 16). See figure 1.

Withdrawal and loss to follow-up
If a patient chooses to withdraw before week 16, all data collected will be permanently deleted. If the patient is lost to follow-up, data collected up to the day of dropout will be used for analysis.

Statistical analysis
Differences in BDI scores between groups as well as adverse effects will be described descriptively only, due to the pilot nature of the study. To investigate whether there is a statistical indication of an effect of healing indicating a later full-scale trial, we will apply the separation test, a statistical procedure for early phase research, to decide whether to pursue further research. The separation test will be based on calculations regarding the mean reduction in symptoms, and the between-group difference from baseline to weeks 8 and 16, and from baseline to day 6 and 12 months for the intervention group (healing and usual care) versus the control group (usual care).

The last author (AEK) will perform the statistical analysis. Data analysis will be done using the IBM statistical package SPSS V.28 (http://www.spss.com).
Qualitative analysis

Qualitative data will be analysed based on a directed qualitative content analysis, because the field will benefit from further description. Categories and codes will be developed inductively from the data and deductively according to themes of the structured interview guide and the research questions. Included themes will be supported by evidence in the form of participants’ statement (quotations).

Patient and public involvement

In this study, patients will be interviewed about their study experiences and the main outcomes of this study are recruitment, willingness to randomisation and other feasibility measures.

Sample size

No sample size calculation is needed for a pilot RCT. The findings of this pilot study will be used to calculate the sample size in a potential future RCT. A study size of n=16 participants, n=8 in each group is chosen to generate sufficient interviews (saturation on that point is assumed) for the qualitative study.

Data handling management

All patient data and the index that links trial numbers with individual participants will be kept under lock, and the key will be in the possession of NAFKAM. Trial number alone will identify all data.

Coding and punching

Data entry will be undertaken at NAFKAM. All data will be read twice to ensure against random bias in the coding and punching process. The first author (TS) will be responsible for obtaining and analysing the qualitative data.

ETHICS AND DISSEMINATION

The patients will be informed about the study through an information folder and verbally by the study nurse, and, if willing to participate, asked to give a written informed consent. The participants will be informed that they can withdraw from the study at any time without any consequences. All patients will follow usual care regardless of healing treatment, and adverse effects will be recorded at each treatment session. No systematic studies have been published on adverse effects of spiritual healing for depression. However, previous research has demonstrated that spiritual healing is associated with low risk. The study will be conducted in accordance with the Helsinki declaration. This protocol was approved by The Regional Committees for Medical and Health Research Ethics (by the identifier 63692) and registered at the Norwegian Center for Research Data (845302) and clinicaltrials.gov (ID: NCT04766242). The results of this protocol will be published in at least two scientific papers in peer-reviewed journals. In addition, results will be presented orally and on posters at national and international conferences. Following the publication in scientific journals, the project will be communicated through the web portal of NAFKAM (www.nafkam.no). The Norwegian authorities will also be notified through written communication about the results of the study.

Data and safety monitoring

A steering group will be responsible for quality control and will meet on a regular basis throughout the study period. The steering group will be convened as an emergency in the event of serious adverse effects associated with the trial to decide on appropriate action to prevent recurrence. Regular meetings will concern any reported adverse effects, protocol violation, the recruitment rate, practical issues concerning local coordination, as well as any issues raised by the participants.

DISCUSSION

To the best of our knowledge, this is the first pilot RCT investigating the feasibility of the study design and the participants’ experience of spiritual healing and usual care for patients with moderate depression in Norway. This research team has previously conducted an observational study investigating self-reported effect of healing, with a prepost design. The rationale for the study was that Norwegian patients with chronic diseases and psychological problems reported frequent use of spiritual healing (14%–36%). Moreover, 38% of patients with cancer in northern Norway reported having used spiritual healing. Generally, most CM interventions are under-researched, taking into consideration that they are widely practised, and limited information is available about their clinical effectiveness and risk profile. Observational studies are well suited to investigate these questions in a real life setting.

Therefore, to get more nuanced information, we aimed to map the conditions patients reported when visiting a healer for the first time, and to evaluate the subjective benefits and risks from the intervention. Results from the above-mentioned observational study reported that a total of 23% of the participants reported psychological complaints such as anxiety and depression. These complaints were reduced from a pretreatment score of 4.7 to a post-treatment score of 2.3, measured by MYMOP. This reduction was achieved after a mean of 4.1 spiritual healing sessions (ranges 1–17). Forty per cent of the participants reported one or more adverse effects after treatment. These were perceived by the participants as minor and transient. However, these results must be interpreted with care since no interference statistical analysis of effect was performed. Due to the lack of a control group, we cannot draw the conclusion that the findings are exclusively due to the spiritual healing treatment.

Based on the findings from the previous observational study, and in preparation for a larger RCT, we want to investigate the recruitment speed, participants’
willingness to be randomised, study adherence, and implementation of healing compared with usual care for moderate depression. We will also investigate the change in severity of depression measured by BDI.

**Strengths and limitations**

This protocol must be understood in light of the study limitations. Because of the COVID-19 pandemic and lockdown of the society, only one healer will be implementing the healing sessions as opposed to the two originally planned. Due to the overload of patients in clinical practice and implementation of pandemic protocols (such as vaccination of patients) the implementation of the trial has been negatively affected. The physicians who will recruit patients to the trial have been occupied with patients with COVID-19. However, several physicians working in five different conventional health clinics will recruit patients to the trial providing an insight on different methods of usual care. A multidisciplinary research team consisting of CM providers, physicians, psychiatrists and researchers will safeguard a methodology in line with a whole system research approach. Lastly, to enhance patient safety, the research team will record adverse effects of both healing and usual care.

**Acknowledgements**

The authors thanks Jane Ekelund and Tine Lillegård Bergli for technical support. The publication charges for this article have been funded by a grant from the publication fund at UiT The Arctic University of Norway. We highly appreciate this service.

**Contributors**

TS and AEK initiated this study, developed the concept and study design, AC, AHI, OK-B and CG contributed with intellectual content. TS wrote the first draft of the manuscript and all authors reviewed subsequent versions of the manuscript. All authors read and approved the final version of the manuscript.

**Funding**

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data are available upon reasonable request.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Trine Stub http://orcid.org/0000-0002-7053-509X

**REFERENCES**

1. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. *Lancet* 2013;382:1575–86.

2. Mykletun A, Knudsen AK, Mathiesen KS. Psykiske lidelser i Norge. *Et folkehelseperspektiv* [Mental disorders in Norway: A public health perspective. Oslo: Norwegian Institute of Public Health, 2009.

3. Breedlove SM, Rosenzweig MR, Watson NV. Biological psychology: an introduction to behavioral, cognitive, and clinical neuroscience. In: Mass: Sinauer associates. 5th, Sunderland, 2007.

4. Wang PS, Aguilar-Gaxiola S, Alonso J, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the who world mental health surveys. *Lancet* 2007;370:841–50.

5. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National comorbidity survey replication. *Arch Gen Psychiatry* 2005;62:593–602.

6. Eisenberg D, Golberstein E, Gollust SE. Help-seeking and access to mental health care in a university student population. *Med Care* 2007;45:594–601.

7. Druss BG, Rosenheck RA. Use of practitioner-based complementary therapies by persons reporting mental conditions in the United States. *Arch Gen Psychiatry* 2000;57:708–14.

8. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. *Am J Psychiatry* 2001;158:289–94.

9. Spinks J, Hollingsworth B. Policy implications of complementary and alternative medicine use in Australia: data from the national health survey. *J Altern Complement Med* 2012;18:371–8.

10. Hansen AH, Kristoffersen AE. The use of CAM providers and psychiatric outpatient services in people with anxiety/depression: a cross-sectional survey. *BMC Complement Altern Med* 2016;16:461.

11. Bazzaran M, Ani CO, Hindman DW, et al. Correlates of complementary and alternative medicine utilization in depressed, underserved African American and Hispanic patients in primary care settings. *J Altern Complement Med* 2008;14:537–44.

12. Jorm AF, Griffiths KM, Christensen H, et al. Actions taken to cope with depression at different levels of severity: a community survey. *Psychol Med* 2004;34:293–9.

13. MacPherson H, Thorpe L, Thomas K, et al. Acupuncture for depression: first steps toward a clinical evaluation. *J Altern Complement Med* 2004;10:1083–91.

14. Dozois DJA, Westra HA. The prevention of anxiety and depression: Theory, research, and practice. In: The nature of anxiety and depression: implication for prevention. Washington: American Psychological Association, 2004: p. 9–41.

15. et alMurthy RS, Bertolote JM, Epping-Jordan J. Mental health: new understanding, new hope2001 14.01. Available: http://www.who.int/whr/2001/en/index.html [Accessed 14 Jan 2009].

16. Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. *PLoS Med* 2008;5:e45.

17. Kirsch I. The Emperor’s New Drugs: Medication and Placebo in the Treatment of Depression. Placebo, Berlin, Heidelberg: Springer Berlin Heidelberg, 2014: 291–303.

18. Arroll B, Elley CR, Fishman T, et al. Antidepressants versus placebo for depression in primary care. *Cochrane Database Syst Rev* 2009;CD007954.

19. Bjørgen D, Kvisle IM. Stiftelsen Kompetansecenter for brukererfaring og tjenesteutvikling (KBT). Etablering av legmiddelfrie behandlingstilbud - Alternativer til medicamentell behandling innen psykisk helsevern In English: Establish drug-free treatment options - Alternatives to drug treatment in mental health care; 2020.

20. Berge T, Replå A, Den indre samtalen. Cognitive therapy in practice. *In: Kognitiv terapi i praksis. English: the inner conversation. Oslo: Gyldendal Norsk Forlag AS, 2004.

21. Brededove SM, Rosenzweig MR, Watson NV. Biological psychology: an introduction to behavioral, cognitive, and clinical neuroscience. In: Mass: Sinauer associates. 5th, Sunderland, 2007.

22. MacPherson H, Hammerschlag R, Lewith G. Acupuncture research strategies for establishing an evidence base. London: Churchill Livingstone, 2007: 260.

23. Shore AG. Long-term effects of energetic healing on symptoms of psychological depression and self-perceived stress. *Altern Ther Health Med* 2004;10:42–8.

24. Richeson NE, Spross JA, Lutz K, et al. Effects of Reiki on anxiety, psychological depression and self-perceived stress. *Altern Ther Health Med* 2004;10:42–8.

25. MacPherson H, Hammerschlag R, Lewith G. Acupuncture research strategies for establishing an evidence base. London: Churchill Livingstone, 2007: 260.

26. MacPherson H, Hammerschlag R, Lewith G. Acupuncture research strategies for establishing an evidence base. London: Churchill Livingstone, 2007: 260.

27. Joyce J, Herbison GP. Reiki for depression and anxiety. *Cochrane Database Syst Rev* 2015;4:CD006833.
28 Kristoffersen AE, Stub T, Knudsen-Baas O, et al. Self-Reported Effects of Energy Healing: A Prospective Observational Study With Pre-Post Design. In: Explore: the Journal of science and healing, 2018.

29 Paterson C, Britten N. In pursuit of patient-centred outcomes: a qualitative evaluation of the ‘measure yourself medical outcome profile’. J Health Serv Res Policy 2000;5:27–36.

30 Thompson TDB, Weiss M. Homeopathy—what are the active ingredients? An exploratory study using the UK medical research council’s framework for the evaluation of complex interventions. BMC Complement Altern Med 2006;6:37.

31 Pennebaker JW, Barger SD, Tiebout J. Disclosure of traumas and health among holocaust survivors. Psychosom Med 1989;51:577–89.

32 Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.

33 Malt UF, Andreaussen OA, Malt Albertsen E, et al. Lærebok i psykiatri. English: Textbook in psychiatry. Oslo: Gyldendal Akademisk, 2017.

34 Foreningen for utgivelse av Norsk legemiddelhåndbok. Terapikapitel T5.5 Depresjoner. (In English: Therapy chapter). In: Norsk legemiddelhåndbok (in English: Norwegian medicine handbook). Oslo, 2013. https://www.lemiddelhandboka.no/T5.5/Depresjoner

35 Steer RA, Cavalieri TA, Leonard DM, et al. Use of the beck depression inventory for primary care to screen for major depression disorders. Gen Hosp Psychiatry 1999;21:106–11.

36 Aickin M. Separation tests for early-phase complementary and alternative medicine comparative trials. Evidence-Based Integrative Medicine 2004;1:225–31.

37 Statens legemiddelverk (Norwegian Medicines Agency). Melding Om mistenkt bivirkning ved bruk AV legemidier (ink. naturlgemidier). Oslo Folkehelseinstituttet; 2009. www.legemiddelverket.no

38 Quinn Patton M. Qualitative research & evaluation methods. Integrating theory and practice. California: SAGE publications, Inc, 2015.

39 Interviews KS. An introduction to qualitative research interviewing. Thousand Oaks California: Sage, 1996.

40 Hsieh H-F, Shannon S. Qualitative health research. J Health Serv Res Policy 2000;5:27–36.

41 Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res 2016;26:1753–60.

42 The World Medical Association (WMA). Declaration of Helsinki—Ethical principles for medical research involving human subjects 1964; 2013. http://www.wma.net/en/30publications/10policies/b3/ [Accessed 24 May 2013].

43 Kristoffersen AE, Stub T, Melhus M, et al. Prevalence and associations for use of a traditional medicine provider in the SAMINOR 1 survey: a population-based study on health and living conditions in regions with SAMI and Norwegian populations. BMC Complement Altern Med 2017;17:530.

44 Risberg T, Lund E, Wist E, et al. Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998;16:6–12.

45 Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci 2011;13:217–24.

46 Paterson C, Britten N. In Pursuit of Patient-Centred Outcomes: A Qualitative Evaluation of the ‘Measure Yourself Medical Outcome Profile’. Journal of Health Services Research & Policy 2000;5:27–36.